Navigation Links
Immediate Treatment of Early MS Patients with Betaferon,Significantly Delayed Permanent Disability

on Betaferon® treatment after the first event suggestive of MS.

About Betaferon® / Betaseron®
Betaferon®, which is marketed in the U.S. and Canada under the trademark Betaseron®, was the first disease-modifying drug introduced for MS and is a well-established treatment around the world. In the U.S., Europe and Japan, Betaferon® has been approved for all relapsing forms of MS. It is able to reduce the number of MS episodes by one-third, and the frequency of moderate to severe episodes by as much as 50 percent. Sixteen years’ follow up of people treated with Betaferon® has shown that it is safe and well tolerated.


References
*Mark S. Freedman, et al: Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT): Effects of Immediate vs. Early Onset of Interferon Beta-1b Treatment, American Academy of Neurology, 59th Annual Meeting


Bayer HealthCare
Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma and as Bayer HealthCare Pharmaceuticals in the US and Canada. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide.


Bayer Schering Pharma
Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company. Its research and business activities are focused on the following areas: Diagnostic Imaging, Hematology/Cardiology, Oncology, Primary Care, Specialized Therapeutics and Women's Healthcare. With innovative products, Bayer Schering Pharma aims for leading positions in specialized markets worldwide. Using new ideas, Bayer
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
2. OREXIGEN Therapeutics Announces Sustained-Release Formulation of Zonisamide Shows Improved Tolerability When Compared to Immediate Release Formulation
3. First of Its Kind Data Show: Immediate Treatment of Early MS Patients with Betaseron Significantly Delayed Permanent Disability
4. Point of Care Strep Tests Speed Treatment, Lower Costs
5. Rapid HIV Testing Increases Possibility of Treatment
6. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
7. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
10. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
11. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
Post Your Comments:
(Date:1/14/2014)...  Luminex Corporation (Nasdaq: LMNX ) today announced that ... 2013 on Monday, February 3, 2014. A press release announcing ... trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... highlights and financial results for the fourth quarter and twelve ...
(Date:1/14/2014)... HILLSBORO, Ore. , Jan. 14, 2014 /PRNewswire-iReach/ -- ... and a targeting guide with accompanying instrumentation to place ... new adjunct to the soft tissue (e.g. ligament) repair ... soft tissue repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ...
(Date:1/14/2014)... N.Y. , Jan. 14, 2014   Oligomerix, Inc. , ... modifying therapeutics for Alzheimer,s disease (AD) and related neurodegenerative ... to Valhalla, NY as of ... laboratory space at New York Medical College. ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Conn., Sept. 21 In a platform presentation at ... the Study of Diabetes (EASD) in Stockholm, investigators for ... the results of a clinical study evaluating a new ... (Profil Institute for Metabolic Research, Neuss, Germany) and colleagues ...
... Inc. (Nasdaq: VVUS ) today announced positive ... Controlled Release Capsules, an investigational therapy for treatment of ... Americans. The findings come from the ... subset of patients who completed the previously reported 56-week ...
Cached Medicine Technology:Results of Linjeta™ Study Versus Insulin Lispro Reported Today in Platform Presentation at EASD Annual Meeting 2Results of Linjeta™ Study Versus Insulin Lispro Reported Today in Platform Presentation at EASD Annual Meeting 3New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 2New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 3New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 4New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 5New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 6
(Date:4/24/2014)... to receive at least if you,re an adolescent and ... found that 15- and 16-year-olds who find pleasure in pro-social ... less likely to become depressed than those who get a ... themselves. , The researchers detail their findings in the ... study focused on the ventral striatum, a brain region that ...
(Date:4/24/2014)... Science Foundation has awarded LSU Health Sciences Center ... Site grant in the amount of $295,635. The ... diverse social and educational backgrounds, underrepresented in the ... The project will provide students with training for ... It will be led by Principal Investigator Dr. ...
(Date:4/23/2014)... was safe and effective in treating patients with ... , according to a new pilot study published ... online. Known as fecal microbiota transplantation, the treatment ... or a nasogastric tube. The findings suggest approaches ... available to patients. , A growing concern, ...
(Date:4/23/2014)... O,Shea, M.D., scientific director at the National Institute of ... named the 2014 recipient of the Ross Prize in ... journal Molecular Medicine . The award will be ... of Sciences in Manhattan, followed by scientific presentations by ... of the National Institutes of Health. , The award, ...
(Date:4/23/2014)... Ind. - Purdue University researchers have developed a way ... cell by using tiny gold particles with tails of ... of agricultural and biological engineering, used gold nanoparticles to ... as BRCA1 messenger RNA splice variants, which can indicate ... of these mRNA splice variants in a cell can ...
Breaking Medicine News(10 mins):Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2
... project to manage the potential shortage of bird flu vaccine ... preparation, would soon be initiated by Chugai Pharmaceutical Company, a ... Health, Labor and Welfare of Japan is said to have ... bird flu vaccine is hoped to being in the next ...
... billion in health reforms. But his off-handed statement has outraged ... there was more mental illness previously which we are not ... on with one’s life. ,This comment was labeled ... he said that in reality mental illness is still considered ...
... bird flu infection in nearly 8 birds, the Hong Kong ... rental system) in possession of animal or bird without prior ... a deduction of five penalty points. ,. ,In ... to pay a fine of 100, 000 HK dollars, according ...
... off at lunch breaks, coughing up ?4,500 for Jiffy breast ... such breast implant operations//, and is getting into the News ... was one of the first to be on their operation ... her mom and a student loan. She said: "You ...
... genetic and environmental factors in the incidence of common ... major research studies// The National Institutes of Health (NIH) ... environment and the disease would form the main focus ... around the significance of genetic variation in increasing or ...
... A new study by Margaret Marshall of Seattle Pacific University ... that the strategy// of expecting the worst results after an ... individuals who adopt such defensive pessimism are not better off ... issue of the journal Cognition and Emotion, the excretes of ...
Cached Medicine News:Health News:NIH To Launch Two Major Gene and Disease Projects Soon 2
The Model 305 is a hand-held, portable, lightweight oximeter designed for spot checking. It has a NiCad rechargeable battery....
A pocket-sized pulse oximeter. Perfect for the physician's office, emergency medicine, hospitals and clinics, and home health care....
... Cost-effective, portable, continuous, or spot ... with alarms and an internal ... and Sleep Study modes make ... the hospital or clinical environment; ...
... Sleep Hand-Held Pulse Oximeter with built-in ... sleep screening studies in the sleep ... With its easy-to-use, 2-key operation, it ... of SpO 2 , pulse rate ...
Medicine Products: